BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-89862175 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-89862175\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07223125-11226@assetmemo.bio
DTSTAMP:20261121T005740Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:JNJ-89862175: Phase 1 readout est. (NCT07223125)
DESCRIPTION:JNJ-89862175\, phase 1\, Advanced Solid Tumors.\nStudy: A Study
  of JNJ-89862175 for Treatment of Advanced Solid Tumors\nEstimated primary
  completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/jnj-89862175#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07223125
URL:https://assetmemo.bio/drug/jnj-89862175#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
